SimBioSys Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
30
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$5.25M
- Investors
-
11
SimBioSys General Information
Description
Developer of a medical platform intended to deploy computational oncology to transform decision-making and patient experience in cancer care. The company's offerings include comprehensive datasets collected during diagnosis into personalized virtual tumors through computational scenario analysis, enabling doctors to provide a better understanding of the disease and get treated accordingly.
Contact Information
Website
www.simbiosys.comCorporate Office
- 320 North Sangamon Street
- 7th floor
- Chicago, IL 60607
- United States
Corporate Office
- 320 North Sangamon Street
- 7th floor
- Chicago, IL 60607
- United States
SimBioSys Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 06-Jan-2025 | $5.25M | Completed | Generating Revenue | ||
| 4. Grant | 18-Nov-2022 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 20-Jul-2021 | Completed | Generating Revenue | |||
| 2. Seed Round | 20-Nov-2018 | $900K | $900K | Completed | Startup | |
| 1. Grant | 01-Jan-2017 | $212K | Completed | Startup |
SimBioSys Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
SimBioSys Patents
SimBioSys Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260207121-A1 | Multi-tissue segmentation and deformation for breast cancer surgery | Pending | 06-Dec-2022 | ||
| WO-2024123484-A1 | Multi-tissue segmentation and deformation for breast cancer surgery | Inactive | 06-Dec-2022 | ||
| US-20250046452-A1 | A method for cancer prognostication using perfusion kinetic analysis of standard-of-care dce mris | Pending | 06-Dec-2021 | ||
| WO-2023107518-A1 | A method for cancer prognostication using perfusion kinetic analysis of standard-of-care dce mris | Inactive | 06-Dec-2021 | ||
| WO-2023081000-A1 | Metabolic modeling for disease prognosis and treatment | Inactive | 03-Nov-2021 | G16H50/50 |
SimBioSys Signals
SimBioSys Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Calculus Venture Capital | Venture Capital | Minority | ||
| Xcellerant Ventures | Venture Capital | Minority | ||
| National Cancer Institute I-Corps | Accelerator/Incubator | |||
| AV8 Ventures | Venture Capital | Minority | ||
| Genoa Ventures | Venture Capital | Minority |
SimBioSys FAQs
-
When was SimBioSys founded?
SimBioSys was founded in 2017.
-
Where is SimBioSys headquartered?
SimBioSys is headquartered in Chicago, IL.
-
What is the size of SimBioSys?
SimBioSys has 30 total employees.
-
What industry is SimBioSys in?
SimBioSys’s primary industry is Decision/Risk Analysis.
-
Is SimBioSys a private or public company?
SimBioSys is a Private company.
-
What is SimBioSys’s current revenue?
The current revenue for SimBioSys is .
-
How much funding has SimBioSys raised over time?
SimBioSys has raised $21.1M.
-
Who are SimBioSys’s investors?
Calculus Venture Capital, Xcellerant Ventures, National Cancer Institute I-Corps, AV8 Ventures, and Genoa Ventures are 5 of 11 investors who have invested in SimBioSys.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process